Journal
MOLECULAR THERAPY
Volume 12, Issue 6, Pages 1013-1022Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2005.08.022
Keywords
spinal muscular atrophy; SMN1 gene product; SMN2 gene product; RNA splicing; alternative splicing; U7 snRNA; gene therapy
Categories
Funding
- NIGMS NIH HHS [R01 GM062287, GM 07311, GM 62287] Funding Source: Medline
Ask authors/readers for more resources
Mutations in one of the duplicated survival of motor neuron (SMN) genes lead to the progressive loss of motor neurons and subsequent development of spinal muscular atrophy (SMA), a common, and usually fatal, hereditary disease. Homozygous absence of the telomeric copy (SMN1) correlates with development of SMA because differential splicing of the centromeric copy (SMN2) leads to exon 7 skipping and predominantly produces a biologically inactive protein isoform. To increase exon 7 inclusion of SMN2, we have designed a series of vectors that express modified U7 snRNAs containing antisense sequences complementary to the 3' splice site of SMN exon 8. Over 20 anti-SMN U7 snRNAs were tested for their ability to promote exon 7 inclusion in the SMN2 gene. Transient expression of anti-SMN U7 snRNAs in HeLa cells modulated SMN2 splicing to -70% exon 7 inclusion in a sequence-specific and dose-dependent manner. Significantly, the administration of anti-SMN U7 snRNPs results in an increase in the concentration of SMN protein. These results suggest that modulation of SMN2 pre-mRNA splicing by modified U7 snRNAs; provides a promising form of gene therapy for the treatment of SMA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available